Moderna, Inc. (NASDAQ:MRNA) Receives Consensus Recommendation of “Hold” from Brokerages

Posted by on Jun 12th, 2023

Shares of Moderna, Inc. (NASDAQ:MRNA – Get Rating) have been given an average rating of “Hold” by the sixteen ratings firms that are currently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating on the company. The average 12-month price target among brokers that have covered the stock in the last year is $179.13.

Several research firms recently commented on MRNA. SVB Leerink cut shares of Moderna from a “market perform” rating to an “underperform” rating and cut their target price for the company from $111.00 to $93.00 in a research note on Friday, February 24th. Royal Bank of Canada began coverage on shares of Moderna in a report on Wednesday, March 1st. They issued an “outperform” rating and a $200.00 price target on the stock. Morgan Stanley lowered their price target on shares of Moderna from $185.00 to $153.00 in a report on Friday, May 5th. JPMorgan Chase & Co. boosted their price target on shares of Moderna from $127.00 to $145.00 and gave the company a “neutral” rating in a report on Monday, April 10th. Finally, SVB Securities lowered shares of Moderna from a “market perform” rating to an “underperform” rating and lowered their target price for the stock from $111.00 to $93.00 in a report on Friday, February 24th.

Moderna Price Performance

Shares of Moderna stock opened at $123.26 on Monday. The firm has a fifty day simple moving average of $136.54 and a 200-day simple moving average of $159.42. The company has a current ratio of 3.46, a quick ratio of 3.26 and a debt-to-equity ratio of 0.04. Moderna has a 1-year low of $115.03 and a 1-year high of $217.25. The stock has a market capitalization of $46.99 billion, a price-to-earnings ratio of 10.65 and a beta of 1.70.

Moderna (NASDAQ:MRNA – Get Rating) last released its earnings results on Thursday, May 4th. The company reported $0.19 EPS for the quarter, beating the consensus estimate of ($1.77) by $1.96. The firm had revenue of $1.86 billion during the quarter, compared to analysts’ expectations of $1.17 billion. Moderna had a net margin of 31.77% and a return on equity of 25.87%. The business’s quarterly revenue was down 69.3% compared to the same quarter last year. During the same period in the prior year, the company earned $8.58 EPS. On average, sell-side analysts expect that Moderna will post -3.15 earnings per share for the current year.

Insider Buying and Selling at Moderna

In related news, CEO Stephane Bancel sold 40,000 shares of the stock in a transaction that occurred on Wednesday, April 12th. The shares were sold at an average price of $156.68, for a total value of $6,267,200.00. Following the sale, the chief executive officer now directly owns 5,411,946 shares in the company, valued at approximately $847,943,699.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Noubar Afeyan sold 15,000 shares of the stock in a transaction that occurred on Wednesday, June 7th. The shares were sold at an average price of $125.91, for a total value of $1,888,650.00. Following the sale, the director now directly owns 2,157,209 shares in the company, valued at approximately $271,614,185.19. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Stephane Bancel sold 40,000 shares of the stock in a transaction that occurred on Wednesday, April 12th. The shares were sold at an average price of $156.68, for a total transaction of $6,267,200.00. Following the completion of the sale, the chief executive officer now owns 5,411,946 shares in the company, valued at $847,943,699.28. The disclosure for this sale can be found here. In the last three months, insiders have sold 431,850 shares of company stock worth $61,018,813. Company insiders own 15.70% of the company’s stock.

Hedge Funds Weigh In On Moderna

Several hedge funds have recently made changes to their positions in the business. RB Capital Management LLC grew its stake in shares of Moderna by 7.5% in the first quarter. RB Capital Management LLC now owns 2,267 shares of the company’s stock valued at $391,000 after buying an additional 158 shares in the last quarter. Synovus Financial Corp boosted its position in shares of Moderna by 8.0% in the first quarter. Synovus Financial Corp now owns 4,049 shares of the company’s stock valued at $704,000 after acquiring an additional 300 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Moderna by 5.1% in the first quarter. Dimensional Fund Advisors LP now owns 987,478 shares of the company’s stock valued at $170,121,000 after acquiring an additional 47,755 shares during the period. Blair William & Co. IL boosted its position in shares of Moderna by 12.4% in the first quarter. Blair William & Co. IL now owns 15,611 shares of the company’s stock valued at $2,689,000 after acquiring an additional 1,724 shares during the period. Finally, Sei Investments Co. boosted its position in shares of Moderna by 41.4% in the first quarter. Sei Investments Co. now owns 58,160 shares of the company’s stock valued at $10,019,000 after acquiring an additional 17,031 shares during the period. 63.11% of the stock is owned by institutional investors.

Moderna Company Profile

(Get Rating)

Moderna, Inc engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.

Featured Articles

Analyst Recommendations for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.